Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene

Hao, Jiali; Xie, Wei‐Fen; Li, Hui; R, Li

doi:10.1515/med-2019-0001

Cited by 8 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ad vector based on PB promoter may target AR positive PCa 41 . Hao et al designed OncoAd.mK5.DD3 vector that effectively inhibited PCa 42 .…”

Section: Virus Vaccinementioning

confidence: 99%

Current status and progress of the development of prostate cancer vaccines

Wang¹,

Zhou²,

Zhu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumor associated antigen (TAA) to activate specific immune response of the body to cancer cells. With continuous maturity of tumor vaccine technology, different forms of prostate cancer vaccines have been developed, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines. In this review, we summarize current status and progress in the development of prostate cancer vaccines.

show abstract

“…Ad vector based on PB promoter may target AR positive PCa 41 . Hao et al designed OncoAd.mK5.DD3 vector that effectively inhibited PCa 42 .…”

Section: Virus Vaccinementioning

confidence: 99%

Current status and progress of the development of prostate cancer vaccines

Wang¹,

Zhou²,

Zhu³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Prostate cancer gene 3 (PCA3/DD3) is a PCaspecific marker identified recently. Hao et al [36] designed OncoAd.mK5.DD3 vector to drive the expression of mK5 (the mutational kringle5 of human plasminogen) by DD3 promoter specially in PCa cells and the results showed that OncoAd.mK5.DD3 was able to inhibit PCa efficiently. Taking advantages of the sensitivity and specificity of DD3 as PCa marker, a test kit Progensa™ (Gen-Probe Inc. San Diego, CA, USA) was developed for the detection of PCa cells in urine [37].…”

Section: Prostate-specific Promotermentioning

confidence: 99%

Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy

Wei

et al. 2021

Front Biosci (Landmark Ed)

View full text Add to dashboard Cite

“…Additionally, mK5 has a stronger effect on the induction of HUVECs apoptosis [13]. Previous studies have shown that OV-mediated mK5 can inhibit the growth of colorectal cancer [14] and prostate cancer [15]. Cancer often involves changes in the growth and proliferation of cells.…”

Section: Introductionmentioning

confidence: 99%

Combined oncolytic adenovirus carrying MnSOD and mK5 genes both regulated by survivin promoter has synergistic inhibitory effect on gastric cancer

Liu¹,

Liu²,

Hu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the major causes of cancer related mortality. The use of oncolytic virus for cancer gene-virotherapy is a new approach for the treatment of human cancers. In this study, a novel Survivin promoter driven recombinant oncolytic adenovirus carrying mK5 or MnSOD gene was constructed, which was modified after deletion of E1B gene. Human plasminogen Kringle 5 mutant ( mK5 ) and manganese superoxide dismutase ( MnSOD ) are both potential tumor suppressor genes. To construct Ad-Surp- mK5 and Ad-Surp- MnSOD oncolytic adenovirus, we hypothesized that the combination of the two viruses would enhance the therapeutic efficacy of GC as compared to the virus alone. The results of the in vitro experiments revealed that the combination of adenovirus carrying mK5 and MnSOD gene exhibited stronger cytotoxicity to GC cell lines as compared to the virus alone, Additionally, the virus could selectively kill cancer cells and human somatic cells. Cell staining, flow cytometry and western blot analysis showed that the combination of two adenovirus containing therapeutic genes could promote the apoptosis of cancer cells. In vivo experiments further verified that Ad-Surp- mK5 in combination with Ad-Surp- MnSOD exhibited significant inhibitory effect on the growth of GC tumor xenograft as compared to the virus alone, and no significant difference was observed in the body weight of treatment and the normal mice. In conclusion, the combination of our two newly constructed recombinant oncolytic adenovirus containing mK5 or MnSOD therapeutic genes could significantly inhibit gastric cancer growth by inducing apoptosis, suggestive of its potential for GC therapy.

show abstract

Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene

Cited by 8 publications

References 30 publications

Current status and progress of the development of prostate cancer vaccines

Current status and progress of the development of prostate cancer vaccines

Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy

Combined oncolytic adenovirus carrying MnSOD and mK5 genes both regulated by survivin promoter has synergistic inhibitory effect on gastric cancer

Contact Info

Product

Resources

About